

# Rapid detection of HIV-1 p24 antigen and of antibodies to HIV-1 and HIV-2 using magnetic immuno-chromatography (MICT)

**Timothy C. Granade, MS**

**HIV Laboratory Branch**

**Division of HIV/AIDS Prevention**

**NCHHSTP/CDC**



# Applications for additional Rapid Testing diagnostics

---

- Blood safety
- Improved surveillance
- Identification of primary HIV infection
- Monitoring anti-viral therapy
- Diagnosis of infected newborns


# Magnetic immunochromatography (MICT)

## MagnaBioSciences, LLC

1. Lateral flow format
2. Uses super-paramagnetic beads as test marker
3. Detects all captured target at test line improving sensitivity
4. Simple to perform
5. Cost/test is comparable to current lateral flow tests

# Rapid Diagnostics

## MBS MICT assay




**Sample  
Application  
Area**



**Test Control**


**Reading area**



# MagnaBioSciences detection instrument – CE certified



# Detection of magnetic field distortion in oscillating magnetic field



Computer software validates the data and derives a normalized numeric value (MAR)

# Detection and differentiation of antibodies to HIV-1 and HIV-2

- Antigens –
  - Protein A as control
  - eight-branched peptide including multiple immuno-dominant regions of HIV-1
  - eight branched peptide for HIV-2
- Protein A/300nm paramagnetic particles
- Dilution of 1:100
- 20 min incubation




# Typical MAR data for HIV antibody-positive and antibody-negative specimens

## Indirect immunoassay – 2<sup>nd</sup> generation

---

		MAR @ 20 min	
Specimen		HIV-1	HIV-2
HIV-1	1	535.8	0
	2	750.6	0
	3	1009.5	0
HIV-2	4	0	1054.8
	5	0	412.0
	6	0	1531.5

---



MAR values for HIV antibody non-reactive specimens (N=265)  
on the multi-branched peptide (MBP) antigen lines for HIV-1 and HIV-2.

**Detection of antibodies to HIV 1 & 2 by MICT compared to detection of HIV-1 and HIV-2 antibodies by EIA/WB reference standard.  
Specimens from US, west and central Africa; N=549**

**Indirect immunoassay**

<b>EIA/WB Result</b>	<b>MICT</b>		
	<b>HIV-1 P</b>	<b>HIV-2 P</b>	<b>HIV N</b>
<b>HIV-1 P</b>	<b>134</b>	<b>0</b>	<b>0</b>
<b>HIV-2 P</b>	<b>0</b>	<b>65</b>	<b>0</b>
<b>N</b>	<b>0</b>	<b>0</b>	<b>350</b>

**Sensitivity (%)**

**100 %**

**Specificity (%)**

**100 %**

# HIV-1/2 antibody detection by MICT

- Detection of HIV-1 seroconversion 13 panels equal to or better than WB but not as good as 3<sup>rd</sup> generation EIA
- HIV-1 subtypes were detectable by the MICT assay using specimens from global locales and commercial sources.
- Would an antibody sandwich assay improve sensitivity?
- Only modification required is the paramagnetic conjugate

# Typical MAR data for HIV antibody-positive and antibody-negative specimens

## Antibody sandwich immunoassay – 3rd generation

		MAR @ 20 min	
Specimen		HIV-1	HIV-2
HIV-1	1	723.3	0
	2	873.7	0
	3	964.6	0
HIV-2	4	0	676.4
	5	0	436.5
	6	0	368.1

**Detection of antibodies to HIV 1 & 2 by MICT compared to detection of HIV-1 and HIV-2 antibodies by the EIA/WB reference standard.  
Specimens from US, west and central Africa; N=237**

**Antibody sandwich immunoassay**

<b>EIA/WB Result</b>	<b>MICT</b>		
	<b>HIV-1 P</b>	<b>HIV-2 P</b>	<b>HIV N</b>
<b>HIV-1 P</b>	<b>117</b>	<b>5</b>	<b>0</b>
<b>HIV-2 P</b>	<b>0</b>	<b>91</b>	<b>0</b>
<b>N</b>	<b>0</b>	<b>1</b>	<b>28</b>

5 HIV-1 SPECIMENS WERE RX ON HIV-2 AGN;  
NO HIV-2 SPECIMENS WERE RX ON HIV-1 AGN

# Detection of HIV-1 p24

## Challenges


- Concentration of p24 (low pg/ml LOD)
- Availability of analyte (Ag/Ab complexes)
- Unique reagents required
- Assay optimization
- Plasma matrix effects

# Detection of HIV-1 p24 by MICT


- Rabbit polyclonal capture antibody
- Mouse monoclonal conjugate
- Running buffer selection
- Assay optimization parameters
  - Incubations, reagent concentrations, materials



# Detection of HIV-1 p24 spiked into running buffer



## Detection of HIV-1 p24 in sample buffer and 50% plasma



# Detection of p24 antigen in seroconversion panels by MICT

Panel	Member	Day	EIA S/CO	WB	VL	p24 S/CO	MICT (MAR)
1	1	14	0.1	N	$2 \times 10^3$	0.2	0
	2	16	0.1	N	$9 \times 10^4$	1.5	13.4
	3	21	0.1	N	$>8 \times 10^5$	$>50$	46.4
	4	23	0.4	N	$>8 \times 10^5$	$>50$	681.0
	5	103	17.9	P	$2 \times 10^4$	0.1	0
2	1	7	0.1	N	$1 \times 10^5$	1.5	1.5
	2	12	0.2	N	$>8 \times 10^5$	32.3	29.0
	3	14	2.5	N	$>8 \times 10^5$	$>44.0$	111.3
	4	19	$>18.2$	N	$>8 \times 10^5$	27.6	42.6
	5	21	$>18.2$	I	$6 \times 10^5$	16.4	20.7

# HIV-1 p24 detection

- Detection of HIV-1 p24 antigen in various HIV-1 subtype culture fluids
- Detection of p24 antigen in spiked plasma specimens with ~250,000 copies of HIV-1 RNA
- Inter-run and intra-run reproducibility was excellent with CVs <12%

# Detection of HIV-1/2 antibodies and p24 antigen by MICT

Panel member	Abbott HIV 1/2 s/co	Abbott p24 agn s/co	Roche PCR	WB_Band Pattern	2nd gen MICT	3rd gen MICT	p24 MICT
AC-01	0.2	0.6	NEG	no Bands	1.5	0	0
AC-02	7.8	>22.7	POS	no Bands	0	0	177.6
AC-03	15.1	2.2	POS	24,55,160	90.9	982.8	0
AC-04	15.6	1.8	POS	24,55,120,160	151.1	794.3	0
AC-05	16.4	1.0	POS	18,24,55,120,160	146.5	1106	0

# Status of MICT based assays


## Next steps

- Reproducible detection of 30 pg/ml in plasma
- Detection of spiked virus at  $2.5 \times 10^5$  virions/ml
- Detection of p24 in seroconversion panels
- Detection of p24 in culture supernatants from various HIV clades (A-G, O)
- Second and third generation aby tests have been developed
- Aby/Ag combination rapid test

# Applications for additional Rapid Testing diagnostics

---

- Detection of HIV-1 p24 in physiologically relevant ranges is feasible
- Rapid p24 testing will be incorporated into more assays
- Applications for p24 testing to be established
- Low-tech readers for objective determinations



# Acknowledgements

## ■ CDC

- Shon Workman
- Ae Youngpairoj
- Michele Owen
- Susan Wells
- Chou Pau
- Angela Holder

## SRP/CDC

- John Hart
- Kelly Jeter
- James Partin

## MagnaBioSciences

- Jim Wyatt
- Ron LaBorde
- Fan Dong
- Dave Pratt